DRL is introducing Leleka BIO™
Predictive R&D Intelligence

Predict clinical success before the first patient is dosed. Leleka BIO™ turns living patient tumors and multi-omics data into an AI “digital twin” capable to assess drug efficacy, resistance for optimal trial stratification—delivering better early decisions, shorter timelines, lower costs, and higher confidence for oncology R&D.

The Challenge

90 % of oncology assets that look “promising” in cell-line and mouse studies still fail in the clinic. Immortalized lines and PDXs simply can’t capture human tumor heterogeneity or real-world biology.

Our Solution

Leleka BIO™ unites an ethically sourced biobank of 3D patient-derived tumor models with a multi-layer AI engine that learns directly from paired clinical outcomes.

How Leleka BIO™ Works

Leleka BIO™ is not just an analytics dashboard—it’s a decision-support platform grounded in biologically validated models.

Why Leleka BIO™ Wins

  • Human biology at the core – fresh patient tumors retain native architecture and heterogeneity
  • Proprietary, AI-ready dataset– molecular + phenotypic + clinical data captured under one roof; unavailable elsewhere.
  • Fast, turnkey deployment – cloud PaaS with secure API or portal access; no new hardware required.

Platform Use-Cases & Commercial Paths

We’re excited to share progress as we expand the biobank, deepen the data, and roll out platform pilots. If you’re passionate about human-centric drug development, let’s connect and explore collaboration! 💬🔬

#Oncology #DrugDiscovery #AI #DigitalTwins #DRL #Biotech

Contract research organization, which provides solutions for pharma and diagnostics companies, including consulting, cancer models development, and various assays for drug development.
©2024 DRL US. . All Rights Reserved.
Designed & Developed by Echoru LLC® in California